Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin for prevention of post-dural puncture headache after cesarean section
IRCT20201215049725N1Phase 3Completed
- Sponsor
- Alborz University of Medical Sciences
- Start
- May 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of oxytocin in post-dural puncture headache (PDPH) (2 arms), sponsored by Alborz University of Medical Sciences. Primary endpoint: Severity of headache after spinal anesthesia. Started May 2021; status: completed.
02
Drugs
oxytocin
03
Conditions
post-dural puncture headache (PDPH)
Beyond the preview
Go deeper on IRCT20201215049725N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201215049725N1.